New hope for Hard-to-Treat cancers: first human trial launches
NCT ID NCT07481357
First seen Mar 24, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This early-stage trial tests a new drug called DA 3501 in people with advanced stomach or pancreatic cancers that have a specific marker (CLDN18.2). The main goals are to find the safest dose and see if the drug shrinks tumors. About 51 adults will receive the drug every three weeks and be closely monitored for side effects and cancer response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.